Summary & Overview
HCPCS G9051: Oncology Treatment Decision-Making Visit
HCPCS Level II code G9051 denotes an oncology visit focused on treatment decision-making after disease staging or restaging. The code captures encounters where clinicians discuss treatment options, supervise or coordinate active cancer-directed therapy, or manage consequences of such therapy. Its use in a Medicare-approved demonstration project highlights its relevance for evolving care models in oncology and for payers evaluating value-based or demonstration-based payment approaches. Nationally, this code matters because it formalizes billing for high-complexity oncology decision encounters that bridge diagnostic staging and therapeutic planning.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical context for G9051, guidance on common billing considerations, and an outline of the payer landscape where this service is relevant. The publication summarizes benchmarks where available, highlights policy and demonstration project implications for Medicare, and clarifies the types of encounters and sites of service appropriate for this code. Data not available in the input are noted where applicable.
Billing Code Overview
HCPCS Level II code G9051 describes an oncology-focused visit in which the primary purpose is treatment decision-making after the cancer has been staged or restaged. This includes discussion of treatment options, supervision or coordination of active cancer-directed therapy, or management of consequences arising from cancer-directed therapy. The service is designed for use in a Medicare-approved demonstration project.
-
Service type: Oncology clinical decision-making and care coordination
-
Typical site of service: Hospital outpatient departments, cancer centers, or other ambulatory oncology settings where staging/restaging and multidisciplinary treatment planning occur
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 64-year-old patient with newly diagnosed stage III non–small cell lung cancer is referred to a medical oncology clinic after pathologic staging and multidisciplinary tumor board review. The oncology visit focuses on treatment decision-making after disease was staged, including discussion of systemic therapy versus chemoradiation, potential enrollment in a Medicare-approved demonstration project, and coordination of initiation of cancer-directed therapy. The oncologist documents review of staging studies, performance status, comorbidities, goals of care, and expected toxicities; discusses risks and benefits of proposed regimens; obtains informed consent for planned systemic therapy; and communicates treatment plan and orders to the infusion center and radiation oncology for coordinated care. Typical workflow includes pre-visit chart review, face-to-face clinic evaluation, discussion with the patient and caregiver, multidisciplinary coordination (phone or electronic messaging) with surgical oncology/radiation oncology, and documentation of treatment decision-making and plan in the medical record.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier | Use when no additional modifier applies to the service. |
22 |